ArticleFrontiers in oncology2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.European journal of haematology · 2026Review
- Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.European journal of haematology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 2 countries.
Fortunato MorabitoBiotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
Elena ZamagniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Concetta ConticelloDivision of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy.
Vincenzo PavoneDepartment of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase, Italy.
Salvatore PalmieriHematology Unit, Ospedale Cardarelli, Napoli, Italy.
Sara BringhenDivision of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
Monica GalliHematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo, Italy.
Silvia MangiacavalliHematology Division, Department of Hematology-Oncology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Daniele DerudasDepartment of Hematology, Businco Hospital, Cagliari, Italy.
Elena RossiIstituto di Ematologia, Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Roma, Italy.
Roberto RiaDepartment of Biomedical Science, Internal Medicine "G. Baccelli", Policlinico, University of Bari "Aldo Moro" Medical School, Bari, Italy.
Lucio CatalanoHematology, AUOP "Federico II", Naples, Italy.
Paola TacchettiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Giuseppe MeleDepartment of Hematology, Hospital Perrino, Brindisi, Italy.
Iolanda Donatella VincelliHematology Unit, Department of Hemato-Oncology and Radiotherapy, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Enrica Antonia MartinoDepartment of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
Ernesto VignaDepartment of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
Antonella BruzzeseDepartment of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
Francesco MendicinoDepartment of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
Cirino BottaDepartment of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
Anna MeleDepartment of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase, Italy.
Lucia PantaniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Serena RocchiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Bruno GaribaldiDivision of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy.
Nicola CascavillaDepartment of Hematology and Bone Marrow Transplant, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Stelvio BallantiInstitute of Haematology and Stem Cell transplantation, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy.
Giovanni TripepiDepartment of Internal Medicine, Nephrology Center of National Research Institute of Biomedicine and Molecular Immunology, Reggio Calabria, Italy.
Ferdinando FrigeriUOC Ematologia a Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano", Caserta, Italy.
Antonetta Pia FalconeDepartment of Hematology and Bone Marrow Transplant, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Clotilde CangialosiU.O.C. Ematologia A. O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Giovanni ReddicontoDepartment of Hematology, Hospital Vito Fazzi, Lecce, Italy.
Giuliana FarinaUOC Ematologia a Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano", Caserta, Italy.
Marialucia BaroneOnco-Hematology, "Tortora" Hospital, Pagani, Italy.
Ilaria RizzelloIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Enrico IaccinoDepartment of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Selena MimmiDepartment of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Paola CurciDepartment of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
Barbara GamberiDivision of Hematology, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Pellegrino MustoDepartment of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
Valerio De StefanoIstituto di Ematologia, Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Roma, Italy.
Maurizio MussoU.O.C. OncoEmatologia e TMO, Dipartimento Oncologico, Palermo, Italy.
Maria Teresa PetrucciDepartment of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Roma, Italy.
Massimo OffidaniHematology Unit, AOU Ospedali Riuniti di Ancona, Ancona, Italy.
Francesco Di RaimondoDivision of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy.
Mario BoccadoroDivision of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
Michele CavoIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Antonino NeriScientific Directorate, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Massimo GentileDepartment of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
Azienda Ospedaliera di Cosenza · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bologna · ITUniversity of Bari Aldo Moro · ITUniversity of Catania · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCasa Sollievo della Sofferenza · ITIstituto di Ematologia di Bologna · ITMagna Graecia University · ITOspedale Sant'Anna · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITCTO Hospital · ITFederico II University Hospital · ITOspedale Antonio Cardarelli · ITOspedale A. Perrino · ITOspedale Papa Giovanni XXIII · ITOspedale Vincenzo Cervello · ITOspedale Vito Fazzi · ITOspedali Riuniti di Ancona · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRS
Indexed as
carfilzomibelotuzumablenalidomidemultiple myelomaprognosisprognostic scorerelapsed/refractorysurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.